Strategic partnerships Recent exclusive licensing with Bionova Scientific and distribution deal with World Fusion in Japan indicate Scarab Genomics’ openness to channel partnerships. This suggests opportunities to position Scarab as a partner for CDMOs and regional distributors to scale adoption of Clean Genome technology.

Global expansion Distribution in Japan plus ongoing CDMO collaboration points to a growth pattern focused on international markets. Sales outreach can target regional biopharma manufacturers and contract manufacturers seeking more stable, higher-yield production platforms for biologics and vaccines.

Technology premium Clean Genome E. coli strains coupled with the C-Flow continuous fermentation system offer a unique value proposition for safer, more stable, and scalable production. Opportunities exist to upsell to research institutions and industry players seeking process robustness and accelerated development timelines.

Vaccine/Therapeutic focus Historical emphasis on tools for vaccine production and conjugate proteins (e.g., Protein D) indicates alignment with vaccine and biologics manufacturers. This creates a targeted sales angle for CDMOs and biotech firms developing vaccines, therapeutics, or protein-based products.

Mid-market growth Revenue in the $1M-$10M band and a small-to-mid-size employee base (11-50) suggests Scarab is agile and hungry for scalable partnerships. Approach mid-market biotechs and specialty manufacturers looking for high-performance strains and continuous production capabilities without the overhead of large incumbents.